Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for Patients with Short Bowel Syndrome (y 2)

        
        1) Publication of STEPS is in preparation. First results were report at the
          AGA 2011 in an abstract: Jeppesen PB, Pertkiewicz M, Seidner DL, O'Keefe S, Heinze H,
          Joelsson B: Teduglutide, a novel analogue of Glucagon-like Peptide 2 (GLP-2), is
          effective and safe in reducing parenteral support volume in short bowel
          syndrome-intestinal failure subjects: Results from a 24-week, placebo-controlled phase
          3 trial (STEPS), Gastroenterology 2011; 140 (5), Supplement 1, S146
        2) Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ.
          Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition
          and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011
          Jul;60(7):902-14. Epub 2011 Feb 11.

About Takeda Pharmaceuticals Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

Additional information about Takeda is available through its corporate website, http://www.takeda.com.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. NPS is advancing two late-stage registration programs. A New Drug Application is undergoing FDA review for Gattex(R) (teduglutide) as a treatment for adult short bowel syndrome (SBS) and a Phase 3 registration study has been completed for Natpara(TM) (recombinant human parathyroid hormone (rhPTH [1-84]) in adult hypoparathyroidism. NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Nycomed (acquired by Takeda Pharmaceutical Company Limited).

Forward-looking statements

This press release contains forward-looking statements. Forward-looking statements include statements regarding Takeda's and NPS' plans, outlook, strategies, results for the future, and other statements that are not descriptions of historical facts. Forward-looking statements may be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "assume," "continue," "seek," "pro forma," "potential," "target," "forecast," "guidance," "outlook" or "intend" or other similar words or expressions of the negative thereof. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors are cautioned not to unduly rely on such forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding Takeda's and NPS' business, including general economic conditions in Japan, the United States and worldwide; (2) competitive pressures and developments; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) actions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates in development; and (8) integration activities with acquired companies.

The forward-looking statements contained in this press release speak only as of the date of this press release, and Takeda and NPS undertake no obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If Takeda and NPS do update or correct one or more of these statements, investors and others should not conclude that Takeda will make additional updates or corrections.

CONTACT: Media Contacts, Takeda Pharmaceutical Company Limited,Public Relations and Investor Relations, +81-3-3278-2037;European media, Tobias Cottmann, +41445551510, tobias.cottmann@takeda.com;NPS Pharmaceuticals, Inc.,Susan Mesco, +1 908-450-5516, smesco@npsp.com